-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: ADCC Platform Characterization
Author:
InnoModels Biotechnology
Release time:
2024-02-04
InnoModels Biotechnology has long been recognized for its innovations in biotechnology, and its ADCC (Antibody Dependent Cytotoxicity) platform is one of the company's major accomplishments. the unique features of the ADCC platform have made InnoModels Biotechnology a leader in the field of oncology immunotherapy and antibody-based therapies.
Efficient Cytotoxicity Assessment
InnoModels's ADCC platform stands out for its efficient cytotoxicity assessment. The platform accurately and rapidly evaluates the interaction between antibodies and target cells, providing reliable data to support antibody therapy research. Through this feature, researchers are able to better understand the potential of antibodies in triggering cytotoxic reactions, providing an important reference for drug development.

Versatile Experimental Design Options
InnoModels' ADCC platform not only provides efficient cytotoxicity assessment, but also supports a wide range of experimental design options. Researchers can select different cell lines, antibodies and target cells according to their specific needs to simulate real in vivo scenarios. This flexibility makes the ADCC platform suitable for a variety of research scenarios, providing researchers with more comprehensive data.
Comprehensive Data Analysis
InnoModels Biotechnology focuses on providing users with comprehensive data analysis tools. Its ADCC platform is able to provide detailed cytotoxicity data, including information on cell kill rate, antibody potency, target cell specificity, and many other aspects. This comprehensive data analysis helps researchers gain a deeper understanding of the mechanisms of antibody therapy and provides a scientific basis for optimizing efficacy.
Highly Standardized Quality Control
InnoModels Biotechnology has very strict quality control for its ADCC platform experiments. Through rigorous experimental procedures and strict quality control standards, the reliability and reproducibility of experimental results are ensured. This high standard of quality control allows researchers to trust the data provided by the ADCC platform and thus advance their research in the field of antibody therapeutics with greater confidence.
Forward-looking technology development
InnoModels Biotechnology has always been committed to advancing the technological development of the ADCC platform. By continually introducing new technologies and methodologies, the company ensures that its ADCC platform remains at the forefront of science and technology. This forward-looking technological development allows researchers to always take advantage of the latest experimental tools, driving continuous innovation in the field of tumor immunotherapy and antibody therapy.
Summary
With its efficient cytotoxicity assessment, diverse experimental design options, comprehensive data analysis, high standard of quality control, and forward-looking technological development, the ADCC platform from InnoModels Biotechnology has become an important tool in the field of tumor immunotherapy and antibody therapeutics research. The features of this platform not only provide strong support for researchers, but also bring new possibilities for advancing the development and clinical application of anticancer drugs.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd